



Report #:

COA261051-047

Page 1 of 2

Certificate of Analysis (CoA) - Finnrick

Date:

Date Tested:

Customer:

Testing material:

Lot Number:

Sample ID:

Content/Potency:

Storage:

Visual Description:

Labeled as:

Manufacturer:

Testing Purpose:

8/10/2026

8/9/2026

Finnrick

Retatrutide

CW7KA2N

BTL261051-047

30 mg

R.T.

Small clear vial: white sample, white label, silver crimp, purple plastic cap.

Retatrutide

N/A

FTIR and HPLC analysis for the identification, purity, potency and composition of a peptide product. It does not provide information on particulate matter, microbial contamination or presence of endotoxins.



| Test                                         | Method        | Specification                                                                  | Result                                                                                           |
|----------------------------------------------|---------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| General Appearance                           | USP<br><630>  | white powder                                                                   | white powder                                                                                     |
| Mass                                         | USP<br><41>   | As recorded                                                                    | 86.4 mg                                                                                          |
| FTIR Identification and Composition Analysis | USP<br><197A> | Sample spectrum should confirm the content of peptide via characteristic bands | FTIR sample spectrum confirms the presence of Retatrutide with addition of excipient(s)/fillers. |
| HPLC Purity of Peptide Assay                 | USP<br><621>  | Specifications: $\geq 98\%$                                                    | 99.9 %                                                                                           |
| HPLC Potency Assay                           | USP<br><621>  | Specifications: 90 – 110% of 30 mg                                             | 25.2 mg (84.1 %)                                                                                 |
| Peptide-to-Excipients Ratio                  | USP<br><1151> | Recommended ratios of (1:2) to (1:10) for (peptide: excipients)                | 25.2 : 61.2 mg (1:2.4)                                                                           |

Andrea Castro, BS  
Scientist-II  
BTLabs

Escarlet Cabrieles, BS  
Scientist-II  
BTLabs

5601 Corporate Way | Suite 206 | West Palm Beach, FL 33407  
Phone: (561) 941-4835  
E-mail: [info@btlabtesting.com](mailto:info@btlabtesting.com) | Website: <https://btlabtesting.com>




Report #:

COA261051-047


Page 2 of 2

Certificate of Analysis (CoA) - Finnrick

FTIR ID and Composition Analysis: Retatrutide Lot CW7KA2N



HPLC Purity and Potency Assay @ 280 nm: Retatrutide Lot CW7KA2N



| Retatrutide Lot CW7KA2N @ 280 nm |                      |              |
|----------------------------------|----------------------|--------------|
| Peak #:                          | Retention Time (min) | Area (mAU*s) |
| 1                                | 9.997                | 1299.5       |

5601 Corporate Way | Suite 206 | West Palm Beach, FL 33407  
Phone: (561) 941-4835  
E-mail: [info@btlabtesting.com](mailto:info@btlabtesting.com) | Website: <https://btlabtesting.com>